Q3 Result Webinar Presentation

November 13, 2026

Imricor's vision is to bring iMR to every cardiac centre in the world

Disclaimer

The material contained in this document is a presentation of general background information on Imricor Medical Systems, Inc. (**Imricor**) and its activities current as of the date of this presentation. It should be read in conjunction with Imricor's periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. None of Imricor, its officers, directors, employees and agents, nor any other person makes any representation or warranty as to the accuracy, completeness or reliability of the information contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (**US GAAP**) and are denominated in US dollars.

This presentation may contain statements that constitute "forward-looking statements". Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding Imricor's intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial condition.

Imricor uses words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements. These forward-looking statements reflect Imricor's current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond its control, and have been made based upon management's expectations and beliefs concerning future developments and their potential effect upon Imricor. There can be no assurance that future developments will be in accordance with Imricor's expectations or that the effect of future developments on Imricor will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Investors and others are cautioned not to place undue reliance on forward-looking statements.

Imricor is under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

Imricor's CHESS Depositary Interests (**CDIs**) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.

Imricor – more than a medical device company

A technology **platform** that is establishing a new medical field: interventional MR **(iMR)**

FIELD

iMR Interventional MR: a new medical field

PROCEDURES

Electrophysiology
Atrial flutter, AFib and VT ablation

Cardiac catheterisation
Right/left heart cath, launched 2026

Future interventions
New procedures, same iMR lab

PLATFORM

MR-safe equipment
Advantage-MR EP Recorder/Stimulator

Software
NorthStar Mapping System

Single-use consumables
Vision-MR ablation and diagnostic catheters

U.S. commercial launch underway

Q3 CY2026 Highlights

2
U.S. hospital customers, both leading children's hospitals

US$188k
Revenue, up 437% on pcp

US$62.1m / A$90m*
Cash at 30 September 2026

14 of 15
FDA submissions for full U.S. platform complete or under review

U.S. commercial launch

- **Rady Children's Hospital–San Diego:** first U.S. customer, establishing the first U.S. commercial iMR cardiac catheterisation program
- **Children's Medical Center Dallas:** second customer two weeks after launch; first commercial outcome of Philips compatibility.
- **Imricor Cardiovascular** launched, opening a U.S. market of 250+ children's and 2,000+ adult hospitals
- **Imricor Finance with DLL:** hospitals finance over 1–7 years; Imricor is paid in full upfront

Regulatory

- **FDA 510(k) pediatric label expansions:** NorthStar and Vision-MR Diagnostic Catheter now cleared for patients of all ages
- **NavTrac / NavTrac-MR submitted:** all 510(k) submissions are now complete
- **PMA manufacturing module** for the Vision-MR Ablation Catheter accepted and closed by FDA (covers 7 products)

Philips partnership

- **Philips Compatibility Declaration** opens the Philips MR installed base to NorthStar for the first time (U.S. and Europe)
- **Joint turnkey cardiac iMR lab** on Philips 1.5T BlueSeal platform, showcased at ESC Congress 2026

Financial

- **Revenue US$188k** (pcp US$35k), from the first U.S. NorthStar sale
- **Dallas installed after quarter end;** that revenue will be recognised in Q4
- **Net loss US$2.9m,** down 17% on pcp
- **Cash US$62.1m**

*FX AUD/USD 0.69

Financial Performance

Profit and loss

US$'000	Q3 2026	Q3 2025
Revenue	188	35
Costs and non-R&D expenses	(4,000)	(3,119)
R&D expenses	(4,220)	(2,507)
Other expense	(7)	(4)
EBITDA	**(8,039)**	**(5,595)**
Depreciation & amortization	(141)	(178)
EBIT	**(8,180)**	**(5,773)**
Finance income (costs), net	528	381
Foreign exchange gain (loss)	306	95
Fair value change	4,436	1,803
Net loss before tax	**(2,910)**	**(3,494)**
Income tax benefit	-	-
Net loss after tax	**(2,910)**	**(3,494)**
Underlying net loss after tax	**(7,651)**	**(5,392)**

Commentary

- Revenue up 440% on prior comparative period (pcp) as the U.S. launch commences.
- Costs and non-R&D expenses increased primarily due to staffing costs ($1,001), partially offset by a decline expense for inventory reserves ($102).
- R&D expenses increased due to higher staffing ($1,316) and professional services ($281) costs.
- Net loss after tax of $2,910 down 17% due to fair value movement of convertible note, which does not have a direct impact on future cashflow

Balance sheet

US$'000	30 Sep 2026	31 Dec 2025
Cash and cash equivalents	62,100	19,502
Marketable securities	-	21,278
Accounts receivable	379	241
Inventory	1,914	1,096
Other current assets	1,259	800
Total current assets	**65,652**	**42,917**
PP&E, net	1,942	1,538
Inventory, long term	731	415
Operating lease right of use assets	468	604
Other long-term assets	512	282
Total long-term assets	**3,653**	**2,839**
Total assets	**69,305**	**45,756**
Accounts payable	832	496
Accrued expenses	1,728	1,620
Current portion of convertible notes	29,107	11,746
Current portion of option liabilities	-	3,158
Other current liabilities	322	351
Total current liabilities	**31,989**	**17,371**
Convertible notes, net of current	-	13,269
Option and warrant liabilities, net of current	1,923	1,829
Long-term contract liabilities	1,086	1,086
Other long-term liabilities	522	678
Total long-term liabilities	**3,531**	**16,862**
Total liabilities	**35,520**	**34,233**
Share capital	229,432	179,121
Accumulated losses	(195,647)	(167,598)
Total equity	**33,785**	**11,523**

Commentary

- Cash and cash equivalents total US$62.1 million/A$90m
- Convertible note held at fair value under US GAAP; outstanding principal and interest at 30 September was $7.1 million
- Option and warrant liabilities relate to securities issued as part of previous financing activities and are held at fair value under US GAAP.
- Current portion of option liabilities were settled during the quarter through the exercise of the underlying CDI options in July

Cash flow

US$'000	Q3 2026	Q3 2025
Net loss	**(2,910)**	**(3,494)**
Other non-cash adjustments	(3,311)	(1,345)
Change in other assets and liabilities	(1,112)	19
Operating cash flows	**(7,333)**	**(4,820)**
Proceeds from maturity (purchases) of marketable securities	6,922	(7,406)
Other investing activities	(503)	(63)
Investing cash flows	**6,419**	**(7,469)**
Proceeds from issuance of common stock (net)	2,167	181
Other financing activities	-	
Financing cash flows	**2,167**	**181**
Net change in cash	1,253	(12,108)
Cash at beginning of period	60,539	50,344
Effect of foreign currency changes on cash	308	103
Cash at 30 September	**62,100**	**38,339**
Marketable securities	**-**	**7,406**
Total cash and marketable securities	**62,100**	**45,745**

Commentary

- Other non-cash adjustments decrease vs. pcp primarily due
  - Decreases in the change in fair value charges;
  - Partially offset by increases in stock-based compensation recognized following achievement of certain U.S. commercial milestones.
- Proceeds from issuance of common stock in Q3 2026 reflect proceeds from the CDI options exercised in July.
- Total cash and marketable securities increased 36% vs. pcp

Regulatory progress

14 of 15 submissions completed

Regulatory progress: FY25 result vs November 26


20 years of work nearing completion

UNITED STATES — device / submission	Pathway	STATUS AT FY25 RESULT (Feb 2026)	STATUS TODAY (Nov 2026)
NorthStar	510(k)	CLEARED	CLEARED
Vision-MR Diagnostic Catheter	510(k)	CLEARED	CLEARED
Vision-MR Diagnostic Cable	510(k)	CLEARED	CLEARED
NorthStar – Pediatric Label Expansion	510(k)	Pending	CLEARED
Vision-MR Diagnostic Catheter – Pediatric Label Expansion	510(k)	Pending	CLEARED
Vision-MR Diagnostic Cable – Pediatric Label Expansion	510(k)	Pending	CLEARED
Vision-MR Dispersive Electrode	510(k)	Submitted	Submitted
Advantage-MR EP Recorder/Stimulator	510(k)	Submitted	Submitted
NavTrac-MR Steerable Introducer and Dilator	510(k)	Pending	Submitted
NavTrac-MR Cable	510(k)	Pending	Submitted
NavTrac-MR Steerable Introducer and Dilator (x-ray use)	510(k)	Pending	Submitted
Vision-MR Ablation Catheter 2.0 / Cable Set 2.0 / RF5000 — PMA Module 1	PMA	Submitted	CLOSED successfully
Vision-MR Ablation Catheter 2.0 / Cable Set 2.0 / RF5000 — PMA Module 2	PMA	Submitted	CLOSED successfully
Vision-MR Ablation Catheter 2.0 / Cable Set 2.0 / RF5000 — PMA Module 3	PMA	Pending	Submitted
Vision-MR Ablation Catheter 2.0 / Cable Set 2.0 / RF5000 — PMA Module 4	PMA	Pending	Pending



Click to watch video

Philips Partnership : Commercial Launch of the iMR Lab Solution



Imricor and Philips leadership at the joint iMR lab solution launch



Signing the combined iMR lab solution agreement, ESC Congress 2026

- **Fourteen years of joint development -** now a commercial iMR lab solution that Philips takes to market with Imricor
- **Philips has extensive sales channels** in Europe and the U.S. to scale the rollout of iMR labs


Source: Philips and Imricor joint announcement, 27 August 2026. US availability varies by configuration and regulatory status.

We are not alone in our thinking or execution



Click to watch video -Interventional Cardiac MR Solution - Philips


We are not alone in our thinking or execution



- **Years of Philips development** behind the interface
- **NorthStar controls the MR scanner** and receives images in real time
- **Tracks Imricor's active catheters** inside the patient

We are not alone in our thinking or execution

- **7 liters of sealed helium**, vs ~1,500 liters in a conventional scanner
- **Light enough for upper floors**, e.g. the cardiology center
- **No quench pipe**, so no external wall needed
- **Wide bore at 1.5T**: patient access without losing image quality
- **Brings MR into the cath lab**, not procedures into the MRI suite



We are not alone in our thinking or execution



- **Philips is backing iMR** with its brand and sales force
- **Imricor products** feature throughout the lab
- **More Imricor technology** sits in the control room

We are not alone in our thinking or execution

- **Philips' own message**, not Imricor's
- **Imricor's view for 20 years**, now shared by Philips



We are not alone in our thinking or execution

AIM-iMR 2026

Amsterdam International Meeting on Interventional Magnetic Resonance

- **First international meeting** devoted entirely to interventional MR (iMR)
- **Organized by the medical community**, not Imricor; Imricor and Philips are co-sponsors
- **Physicians worldwide are adopting iMR**, with Imricor at the center of the field



Summary and Q&A

INVESTMENT HIGHLIGHTS

1. **Global leader** in MR conditional systems and devices
2. **US$15bn market** growing at 15%
3. **No competition**
4. **Safety tailwinds** with rising concerns about radiation exposure
5. **Close partnerships** with MR manufacturers
6. **Strong balance sheet:** US$62m / A$90m at September 30
7. **Commercialising now** in the US

